Challenges and optimal strategies of CAR T therapy for hematological malignancies

Abstract. Remarkable improvement relative to traditional approaches in the treatment of hematological malignancies by chimeric antigen receptor (CAR) T-cell therapy has promoted sequential approvals of eight commercial CAR T products within last 5 years. Although CAR T cells’ productization is now r...

Full description

Bibliographic Details

Published in:	Chinese Medical Journal
Main Authors:	Yajing Zhang, Yang Xu, Xiuyong Dang, Zeyu Zhu, Wenbin Qian, Aibin Liang, Weidong Han, Peifang Wei
Format:	Article
Language:	English
Published:	Wolters Kluwer 2023-02-01
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000002476